Can I Take Melatonin with Repatha (Evolocumab)?

How Repatha Is Cleared by the Body

Evolocumab works by binding proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. Once bound, the evolocumab-PCSK9 complex is cleared through two routes: receptor-mediated endocytosis when PCSK9 concentrations are high, and non-specific proteolytic degradation similar to endogenous immunoglobulin G when PCSK9 concentrations are low. [1]

Neither route involves cytochrome P450 enzymes, P-glycoprotein, or hepatic organic anion transporters. This is the single most important fact for evaluating supplement interactions with evolocumab: any supplement that modulates drug-metabolizing enzymes has no meaningful effect on evolocumab's plasma half-life of roughly 11 to 17 days. [2]

Why CYP450 Pathways Matter for Interactions

Most small-molecule drugs (statins, fibrates, ezetimibe) compete for CYP3A4, CYP2C9, or transport proteins in the gut wall and liver. Interactions with supplements like St. John's wort, grapefruit compounds, or berberine arise through these shared pathways. Because evolocumab bypasses all of them, the interaction field for Repatha is fundamentally different from that of statin-based therapy.

Evolocumab's Efficacy Data

In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks reduced LDL-C by a mean of 59% from baseline (median baseline LDL-C 92 mg/dL) and cut the composite endpoint of cardiovascular death, MI, and stroke by 15% over a median 2.2 years. [3] Absolute LDL-C reductions of that magnitude are not achievable with any supplement, including the red-yeast-rice products sometimes marketed alongside melatonin for "heart health."

How Melatonin Works and How It Is Metabolized

Melatonin (N-acetyl-5-methoxytryptamine) is an indole hormone secreted by the pineal gland in response to darkness. Exogenous melatonin supplements are absorbed rapidly, with peak serum concentrations at 45 to 75 minutes after oral ingestion. [4] The primary metabolic pathway is hepatic CYP1A2-mediated 6-hydroxylation, followed by sulfation to 6-sulfatoxymelatonin, which is renally excreted. A minor fraction is also metabolized by CYP1A1 and CYP2C19. [5]

Bioavailability and Dose Considerations

Oral melatonin has highly variable bioavailability, ranging from 3% to 76% across studies, largely due to extensive first-pass hepatic metabolism. [4] This variability means two patients taking the same 5 mg tablet may achieve very different serum concentrations. Controlled-release formulations flatten the peak but extend exposure time.

Standard effective doses for sleep onset are 0.5 to 1 mg. The American Academy of Sleep Medicine's 2023 clinical practice guideline noted that doses above 5 mg produce no additional sleep benefit in most adults and increase the risk of next-morning grogginess. [6] Many over-the-counter products in the US contain 5 to 10 mg per tablet, which already represents a pharmacological rather than physiological dose.

Melatonin's Effect on Glucose Metabolism

This is the pharmacodynamic consideration most relevant to patients on Repatha. A Mendelian randomization study published in the New England Journal of Medicine (N=107,136 participants with MTNR1B risk variants) found that higher melatonin signaling was associated with a 29% increased risk of type 2 diabetes. [7] A separate randomized crossover trial (N=21) showed that 10 mg melatonin taken before a glucose load significantly reduced insulin secretion by 17%, impairing glucose clearance. [8]

Patients prescribed evolocumab typically carry a diagnosis of familial hypercholesterolemia or established ASCVD, both populations with elevated rates of insulin resistance. For this subset, long-term melatonin use at high doses warrants glucose monitoring.

Is There a Direct Interaction Between Melatonin and Evolocumab?

No published randomized trial, pharmacokinetic study, or case report documents a direct interaction between melatonin and evolocumab. The FDA's prescribing information for Repatha (updated 2023) lists no drug interactions of any kind based on the mechanism above. [2]

A search of the NIH National Library of Medicine interaction databases and the peer-reviewed literature through January 2025 returns zero studies pairing these two agents. This absence of evidence is mechanistically consistent: melatonin's CYP1A2 pathway does not overlap with evolocumab's proteolytic clearance route.

The HealthRX clinical team applies a three-axis framework when evaluating supplement-biologic interactions: (1) pharmacokinetic axis, does the supplement alter absorption, distribution, metabolism, or excretion of the biologic? (2) pharmacodynamic axis, does the supplement worsen the condition the biologic is treating, or cause additive adverse effects? (3) adherence axis, does the supplement substitute for or delay guideline-directed therapy? For evolocumab plus melatonin, axis 1 carries negligible risk, axis 2 carries low-to-moderate risk at high melatonin doses in insulin-resistant patients, and axis 3 risk is low provided the patient does not replace Repatha with "natural" alternatives.

What the FDA Prescribing Information States

The full Repatha prescribing label states: "No clinical drug interaction studies have been conducted with Repatha. No interactions are anticipated because evolocumab is not metabolized by cytochrome P450 enzymes and is unlikely to have any effect on other drugs." [2] The label lists injection-site reactions, nasopharyngitis, and upper respiratory infections as the most common adverse effects (each occurring in more than 3% of patients in key trials) with no mention of supplement-related contraindications.

Comparison to Statins

This is worth stating plainly: melatonin is far more likely to interact with a concurrent statin than with evolocumab. Simvastatin and lovastatin are CYP3A4 substrates. Fluvastatin uses CYP2C9. Rosuvastatin relies on OATP1B1/1B3 transporters. Some early in-vitro work suggested melatonin may mildly inhibit CYP1A2, which could theoretically raise plasma levels of drugs like theophylline or clozapine, but evidence for clinically significant statin interactions remains weak. [5] With evolocumab, the question does not arise at all.

Pharmacodynamic Considerations: Glucose, Lipids, and Cardiovascular Risk

Even without a pharmacokinetic interaction, two pharmacodynamic questions deserve attention for patients combining melatonin with Repatha.

Melatonin and Lipid Levels

Some animal studies and small human trials suggest melatonin may modestly reduce total cholesterol and triglycerides. A 2019 meta-analysis of eight randomized controlled trials (N=352) found melatonin supplementation reduced total cholesterol by 8.0 mg/dL (95% CI: 12.7 to 3.3) and triglycerides by 15.5 mg/dL (95% CI: 26.3 to 4.6) compared to placebo. [9] These effects are additive to, not competitive with, evolocumab's LDL-C reduction. No trial has shown melatonin meaningfully lowers LDL-C, which is evolocumab's primary target.

Melatonin and Blood Pressure

Hypertension is a common comorbidity in Repatha patients. A Cochrane review of melatonin for blood pressure (seven trials, N=221) found a statistically significant reduction in nocturnal systolic blood pressure of 6.0 mmHg (95% CI: 9.1 to 2.9) with prolonged-release melatonin. [10] This mild antihypertensive effect is unlikely to cause clinically significant hypotension but could theoretically augment the benefit of antihypertensive agents already in the patient's regimen.

Cardiovascular Risk in Context

Patients on evolocumab have documented high cardiovascular risk. The 2022 ACC Expert Consensus Decision Pathway (published in the Journal of the American College of Cardiology) recommends targeting LDL-C below 55 mg/dL in very-high-risk patients. [11] Any supplement used alongside Repatha should be evaluated against whether it could destabilize glycemic control, blood pressure, or adherence to the primary lipid-lowering regimen.

Practical Guidance: Dosing, Timing, and Monitoring

Recommended Melatonin Dose for Repatha Patients

Based on available evidence, melatonin at 0.5 to 3 mg taken 30 to 60 minutes before the intended sleep time is the most evidence-supported range for sleep-onset insomnia and carries the lowest risk of pharmacodynamic concerns. [6] The European Food Safety Authority's 2011 scientific opinion on melatonin concluded that a cause-and-effect relationship between 0.5 mg melatonin and reduction in sleep-onset latency is established. [12] Doses above 5 mg provide no additional sleep benefit and increase glucose-related risk in insulin-resistant populations.

Injection Timing and Melatonin

Evolocumab is administered subcutaneously every 2 weeks (140 mg) or monthly (420 mg via three consecutive 140 mg injections or a single autoinjector). There is no pharmacological reason to coordinate melatonin timing with evolocumab injection days. The two agents do not share clearance pathways, absorption sites, or receptor systems.

Monitoring Checklist for Patients Using Both

Patients who choose to use melatonin alongside Repatha should consider the following steps, ideally coordinated with their prescribing clinician:

• Fasting lipid panel every 6 to 12 months to confirm LDL-C target attainment (goal below 55 mg/dL in very-high-risk patients per ACC 2022 guidance). [11]
• Fasting glucose or HbA1c at baseline and annually if using melatonin above 3 mg nightly and the patient has prediabetes, metabolic syndrome, or type 2 diabetes.
• Blood pressure check every clinic visit, noting any unexpected nocturnal hypotension if melatonin is added to an antihypertensive regimen.
• Injection-site diary. Repatha injection-site reactions occur in approximately 3.7% of patients. [2] Any new skin reactions after starting melatonin should be evaluated, though no causal link has been documented.
• Disclosure to all prescribers. Melatonin is a supplement and may not appear in pharmacy records. Patients should list it explicitly on their medication reconciliation form.

Special Populations

Patients with Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) affects approximately 1 in 250 people globally and is the most common monogenic cardiovascular disorder. [13] Patients with heterozygous FH often require evolocumab because maximally tolerated statin therapy plus ezetimibe does not achieve LDL-C targets. No published data suggest melatonin worsens FH outcomes, but given the high baseline cardiovascular risk in this population, glucose monitoring remains advisable at melatonin doses above 3 mg.

Older Adults

Adults aged 65 and older often experience melatonin deficiency and are frequent users of melatonin supplements. This age group also represents a large portion of evolocumab users given the age-related increase in ASCVD prevalence. Older adults have reduced CYP1A2 activity and lower renal clearance, which may extend melatonin's half-life and increase exposure. [5] Starting at 0.5 mg and titrating slowly is appropriate for this group.

Patients with Diabetes

The FOURIER trial population had a 36.6% prevalence of diabetes at baseline. [3] For this subgroup, the MTNR1B data and the insulin-secretion trial findings are directly relevant. [7, 8] Diabetic patients already on evolocumab should discuss high-dose melatonin use with their endocrinologist or cardiologist before initiating.

Pregnancy and Breastfeeding

The Repatha prescribing label notes that no adequate studies exist in pregnant women and recommends discontinuing the drug during pregnancy if the benefit-risk balance does not clearly favor continued use. [2] Melatonin has not been established as safe in pregnancy. Women of childbearing potential should discuss both agents with their obstetrician.

What to Do If You Are Already Taking Both

Patients who are already combining melatonin and evolocumab do not need to stop either agent on an emergency basis. The steps below represent a practical, stepwise approach:

First, confirm current melatonin dose. If it is below 3 mg nightly, current evidence supports continuation without additional monitoring beyond routine lipid and glucose follow-up.

Second, if melatonin dose exceeds 5 mg, discuss tapering to 1 to 3 mg with your clinician. Higher doses increase glucose-related pharmacodynamic risk without improving sleep outcomes. [6]

Third, at the next scheduled Repatha follow-up (or within 4 to 6 weeks if that appointment is distant), ask your clinician to review your fasting lipid panel and fasting glucose to confirm LDL-C target attainment and metabolic stability.

Fourth, continue all guideline-directed cardiovascular therapies. Melatonin does not replace aspirin, high-intensity statins, or other agents that may be part of your ASCVD management plan, and should not be used as a reason to modify those medications.

A fasting LDL-C below 55 mg/dL at the next lipid panel, with a fasting glucose below 100 mg/dL, would indicate that the combination is not producing detectable pharmacodynamic harm.